Friday, June 5, 2026

Samsung Bioepis Launches SBE303: The First ADC Drug Candidate Targeting Nectin-4 in Cancer Trials

Samsung Bioepis has begun Phase 1 trials for its ADC candidate SBE303, targeting solid tumors, set to continue until July 2030.

Brivaracetam vs. Levetiracetam: Which Epilepsy Drug Offers Better Safety and Efficacy?

Samjin Pharmaceutical launches Bricetam Tablets, improving epilepsy treatment with fewer side effects and better adherence for patients.

Kim Jong Un’s Hardline Stance: What Does It Mean for South Korea and the U.S.?

Kim Jong Un's speech at the Supreme People's Assembly emphasizes hostility towards South Korea while adopting a softer tone towards the U.S.

Tag: schizophrenia

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Bukwang Pharma Wins Phase 3 Approval to Expand Latuda Into Adjunctive Treatment for Major Depression

Bukwang Pharmaceutical received approval for a Phase 3 clinical trial of Lurasidone as an adjunctive treatment for MDD.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.